Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL

被引:219
作者
Herman, Sarah E. M. [1 ]
Mustafa, Rashida Z. [1 ]
Gyamfi, Jennifer A. [1 ]
Pittaluga, Stefania [2 ]
Chang, Stella [3 ]
Chang, Betty [3 ]
Farooqui, Mohammed [1 ]
Wiestner, Adrian [1 ]
机构
[1] NHLBI, Hematol Branch, Bethesda, MD 20892 USA
[2] NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA
[3] Pharmacyclics Inc, Sunnyvale, CA USA
基金
美国国家卫生研究院;
关键词
CHRONIC LYMPHOCYTIC-LEUKEMIA; TYROSINE KINASE BTK; TARGETING BTK; OPEN-LABEL; ACTIVATION; LYMPHOMA; PCI-32765; THERAPY; MICROENVIRONMENT; BORTEZOMIB;
D O I
10.1182/blood-2014-02-548610
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chronic lymphocytic leukemia (CLL) cells depend on microenvironmental factors for proliferation and survival. In particular, tissue-resident CLL cells show prominent activation of both B-cell receptor (BCR) and NF-kappa B pathways. We evaluated the in vivo effects of ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor on tumor cell activation and proliferation in the blood, lymph node, and bone marrow of patients with CLL. Applying validated pathway-specific gene signatures, we detected a rapid and sustained downregulation of BCR and NF-kappa B signaling in CLL cells from both the peripheral blood and tissue compartments during ibrutinib treatment. Ibrutinib reduced phosphorylation of PLC gamma 2 and ERK and decreased nuclear protein expression of NF-kappa B p50. Ibrutinib significantly decreased tumor proliferation and expression of surface activation markers CD69 and CD86, independent of prognostic factors such as IGHV mutational status, chromosome 17p deletion, or prior treatment history. Interestingly, stronger inhibition of BCR signaling in lymph node resident CLL cells after one dose of ibrutinib was associated with a higher rate of nodal response at the end of cycle 2. Together, these data validate on-target effects of BTK inhibition in the tissue compartments and demonstrate that ibrutinib effectively inhibits pathways that promote tumor cell activation and proliferation in vivo. This study is registered at www.clinicaltrials.gov as #NCT01500733.
引用
收藏
页码:3286 / 3295
页数:10
相关论文
共 49 条
[1]   Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies [J].
Advani, Ranjana H. ;
Buggy, Joseph J. ;
Sharman, Jeff P. ;
Smith, Sonali M. ;
Boyd, Thomas E. ;
Grant, Barbara ;
Kolibaba, Kathryn S. ;
Furman, Richard R. ;
Rodriguez, Sara ;
Chang, Betty Y. ;
Sukbuntherng, Juthamas ;
Izumi, Raquel ;
Hamdy, Ahmed ;
Hedrick, Eric ;
Fowler, Nathan H. .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (01) :88-94
[2]   Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia [J].
Amrein, Philip C. ;
Attar, Eyal C. ;
Takvorian, Tak ;
Hochberg, Ephraim P. ;
Ballen, Karen K. ;
Leahy, Kathleen M. ;
Fisher, David C. ;
LaCasce, Ann S. ;
Jacobsen, Eric D. ;
Armand, Philippe ;
Hasserjian, Robert P. ;
Werner, Lillian ;
Neuberg, Donna ;
Brown, Jennifer R. .
CLINICAL CANCER RESEARCH, 2011, 17 (09) :2977-2986
[3]  
Brown J, 2013, HAEMATOLOGICA, V98, P217, DOI 10.3324/haematol.2013.086207
[4]   Bruton Tyrosine Kinase (BTK) and Its Role in B-cell Malignancy [J].
Buggy, Joseph J. ;
Elias, Laurence .
INTERNATIONAL REVIEWS OF IMMUNOLOGY, 2012, 31 (02) :119-132
[5]   Nurture versus Nature: The Microenvironment in Chronic Lymphocytic Leukemia [J].
Burger, Jan A. .
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2011, :96-103
[6]   Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia [J].
Byrd, John C. ;
Furman, Richard R. ;
Coutre, Steven E. ;
Flinn, Ian W. ;
Burger, Jan A. ;
Blum, Kristie A. ;
Grant, Barbara ;
Sharman, Jeff P. ;
Coleman, Morton ;
Wierda, William G. ;
Jones, Jeffrey A. ;
Zhao, Weiqiang ;
Heerema, Nyla A. ;
Johnson, Amy J. ;
Sukbuntherng, Juthamas ;
Chang, Betty Y. ;
Clow, Fong ;
Hedrick, Eric ;
Buggy, Joseph J. ;
James, Danelle F. ;
O'Brien, Susan .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (01) :32-42
[7]   Signalling crosstalk in B cells: managing worth and need [J].
Cancro, Michael P. .
NATURE REVIEWS IMMUNOLOGY, 2009, 9 (09) :657-661
[8]  
Chang BY, 2013, J CLIN ONCOL, V31
[9]   BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity [J].
Cheng, S. ;
Ma, J. ;
Guo, A. ;
Lu, P. ;
Leonard, J. P. ;
Coleman, M. ;
Liu, M. ;
Buggy, J. J. ;
Furman, R. R. ;
Wang, Y. L. .
LEUKEMIA, 2014, 28 (03) :649-657
[10]  
Chiorazzi N., 2005, NEW ENGL J MED, V352, P804, DOI [DOI 10.1056/NEJMRA041720, 10.1002/9781444300857.ch36, 10.1056/NEJMra041720]